High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry

Giuseppe Corona, Caterina Elia, Bruno Casetta, Sergio Frustaci, Giuseppe Toffoli

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: The most valuable treatment option for breast, prostate and lung carcinomas is at present represented by a low dose of docetaxel, administered on a weekly basis. A better understanding of docetaxel pharmacokinetic and pharmacodynamic profiles could lead to an improvement in this dose regimen efficacy. Methods: In this study a high-throughput method is described for the rapid quantification of docetaxel for large clinical pharmacology investigations. This analytical approach is based on an automatic on-line purification and enrichment technique followed by a measurement in tandem mass spectrometry through Multiple Reaction Monitoring. Results: The assay was validated over a 0.15-1500ng/mL range. Intra-day precision ranged from 1.9% to 6.4%, while the inter-day was between 7.6% and 11.2%. The mean deviation from the nominal value ranged from -0.5% to 5.6% for the intra-day, and from -0.4% to 3.1% for the inter-day assay. Clinical applicability was demonstrated by measuring plasma pharmacokinetics in patients receiving weekly 25-35mg/m2 of docetaxel. Conclusion: The proposed LC-MS/MS assay was found to have a better performance than previously reported methods in terms of sensitivity and sample preparation. It does not require any laborious pre-analytical manipulation and can be easily employed in large clinical pharmacology studies.

Original languageEnglish
Pages (from-to)358-364
Number of pages7
JournalClinica Chimica Acta
Volume412
Issue number3-4
DOIs
Publication statusPublished - Jan 30 2011

Fingerprint

docetaxel
Liquid chromatography
Tandem Mass Spectrometry
Liquid Chromatography
Mass spectrometry
Throughput
Plasmas
Assays
Pharmacokinetics
Clinical Pharmacology
Pharmacodynamics
Purification
Prostate
Breast
Carcinoma
Lung
Monitoring

Keywords

  • Docetaxel
  • LC-MS/MS
  • On-line extraction
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry. / Corona, Giuseppe; Elia, Caterina; Casetta, Bruno; Frustaci, Sergio; Toffoli, Giuseppe.

In: Clinica Chimica Acta, Vol. 412, No. 3-4, 30.01.2011, p. 358-364.

Research output: Contribution to journalArticle

Corona, Giuseppe ; Elia, Caterina ; Casetta, Bruno ; Frustaci, Sergio ; Toffoli, Giuseppe. / High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry. In: Clinica Chimica Acta. 2011 ; Vol. 412, No. 3-4. pp. 358-364.
@article{2473ade8c57346fba13a396b6491ef2b,
title = "High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry",
abstract = "Background: The most valuable treatment option for breast, prostate and lung carcinomas is at present represented by a low dose of docetaxel, administered on a weekly basis. A better understanding of docetaxel pharmacokinetic and pharmacodynamic profiles could lead to an improvement in this dose regimen efficacy. Methods: In this study a high-throughput method is described for the rapid quantification of docetaxel for large clinical pharmacology investigations. This analytical approach is based on an automatic on-line purification and enrichment technique followed by a measurement in tandem mass spectrometry through Multiple Reaction Monitoring. Results: The assay was validated over a 0.15-1500ng/mL range. Intra-day precision ranged from 1.9{\%} to 6.4{\%}, while the inter-day was between 7.6{\%} and 11.2{\%}. The mean deviation from the nominal value ranged from -0.5{\%} to 5.6{\%} for the intra-day, and from -0.4{\%} to 3.1{\%} for the inter-day assay. Clinical applicability was demonstrated by measuring plasma pharmacokinetics in patients receiving weekly 25-35mg/m2 of docetaxel. Conclusion: The proposed LC-MS/MS assay was found to have a better performance than previously reported methods in terms of sensitivity and sample preparation. It does not require any laborious pre-analytical manipulation and can be easily employed in large clinical pharmacology studies.",
keywords = "Docetaxel, LC-MS/MS, On-line extraction, Therapeutic drug monitoring",
author = "Giuseppe Corona and Caterina Elia and Bruno Casetta and Sergio Frustaci and Giuseppe Toffoli",
year = "2011",
month = "1",
day = "30",
doi = "10.1016/j.cca.2010.11.010",
language = "English",
volume = "412",
pages = "358--364",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "3-4",

}

TY - JOUR

T1 - High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry

AU - Corona, Giuseppe

AU - Elia, Caterina

AU - Casetta, Bruno

AU - Frustaci, Sergio

AU - Toffoli, Giuseppe

PY - 2011/1/30

Y1 - 2011/1/30

N2 - Background: The most valuable treatment option for breast, prostate and lung carcinomas is at present represented by a low dose of docetaxel, administered on a weekly basis. A better understanding of docetaxel pharmacokinetic and pharmacodynamic profiles could lead to an improvement in this dose regimen efficacy. Methods: In this study a high-throughput method is described for the rapid quantification of docetaxel for large clinical pharmacology investigations. This analytical approach is based on an automatic on-line purification and enrichment technique followed by a measurement in tandem mass spectrometry through Multiple Reaction Monitoring. Results: The assay was validated over a 0.15-1500ng/mL range. Intra-day precision ranged from 1.9% to 6.4%, while the inter-day was between 7.6% and 11.2%. The mean deviation from the nominal value ranged from -0.5% to 5.6% for the intra-day, and from -0.4% to 3.1% for the inter-day assay. Clinical applicability was demonstrated by measuring plasma pharmacokinetics in patients receiving weekly 25-35mg/m2 of docetaxel. Conclusion: The proposed LC-MS/MS assay was found to have a better performance than previously reported methods in terms of sensitivity and sample preparation. It does not require any laborious pre-analytical manipulation and can be easily employed in large clinical pharmacology studies.

AB - Background: The most valuable treatment option for breast, prostate and lung carcinomas is at present represented by a low dose of docetaxel, administered on a weekly basis. A better understanding of docetaxel pharmacokinetic and pharmacodynamic profiles could lead to an improvement in this dose regimen efficacy. Methods: In this study a high-throughput method is described for the rapid quantification of docetaxel for large clinical pharmacology investigations. This analytical approach is based on an automatic on-line purification and enrichment technique followed by a measurement in tandem mass spectrometry through Multiple Reaction Monitoring. Results: The assay was validated over a 0.15-1500ng/mL range. Intra-day precision ranged from 1.9% to 6.4%, while the inter-day was between 7.6% and 11.2%. The mean deviation from the nominal value ranged from -0.5% to 5.6% for the intra-day, and from -0.4% to 3.1% for the inter-day assay. Clinical applicability was demonstrated by measuring plasma pharmacokinetics in patients receiving weekly 25-35mg/m2 of docetaxel. Conclusion: The proposed LC-MS/MS assay was found to have a better performance than previously reported methods in terms of sensitivity and sample preparation. It does not require any laborious pre-analytical manipulation and can be easily employed in large clinical pharmacology studies.

KW - Docetaxel

KW - LC-MS/MS

KW - On-line extraction

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=78650231840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650231840&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2010.11.010

DO - 10.1016/j.cca.2010.11.010

M3 - Article

VL - 412

SP - 358

EP - 364

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 3-4

ER -